Replies to post #86083 on Biotech Values

[ariadndndough]

rkrw regarding chemgenex appears aria is better also or is this a unfair comparison

AP534 results also better than Chemgenex
ago Chemgenex also published the results of their Phase 2/3 Omacetaxine trial in pts with the T315I mutation.
http://ash.confex.com/ash/2009/webprogra...

Omacetaxine achieved major molecular response (defined as both both complete and partial cytogenetic) in 15% of pts. In a similar patient population (T315I), AP534 achieved a 33% cytogenetic response rate, more than double that of Omacetaxine. Rating :

[DonShimoda]

dough, it'll be interesting to see how ariad designs a phase 2/3 trial for AP534. I'm assuming it'll be similar to nilotinib and dasatinib (eg interventional, open label) when they went directly to a phase 2/3 registration trial. What will be interesting is the degree to which ariad will target enrollment of patients with the T315I mutation. Looking at the data from today's abstract one could conclude that AP534 is equally as potent in chronic CML patients with no mutations.